SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?

被引：1

作者：

Frustaci, Anna Maria ^{[1
]}

Deodato, Marina ^{[1
]}

Zamprogna, Giulia ^{[1
]}

Cairoli, Roberto ^{[1
]}

Montillo, Marco ^{[1
]}

Tedeschi, Alessandra ^{[1
]}

机构：

[1] ASST Grande Osped Metropolitano Niguarda, Dept Hematol, Niguarda Canc Ctr, Milan, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 06期

关键词：

CLL; CIRS; novel therapies; ibrutinib; venetoclax; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; ELDERLY-PATIENTS; OPEN-LABEL; CLL; IBRUTINIB; OUTCOMES; RITUXIMAB; SURVIVAL; VENETOCLAX;

D O I：

10.1016/j.clml.2021.11.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The importance of coexisting conditions in chronic lymphocytic leukemia (CLL) outcome has been increasingly recognized over the past years. The role of comorbidities to predict patients??? vulnerability toward immunochemotherapy has been well establish, especially since some of the tools commonly used to evaluate patients??? fitness were employed to determine treatment eligibility in randomized trials. Nevertheless, is it still unclear how much fitness weights on treatment outcome with targeted agents and which assessment should be preferred. There are key differences in the toxicity profile between novel agents that are getting much more evident in retrospective, real-life experiences, rather than clinical trials. Therefore, an individual patient???s comorbid medical conditions may be a deciding factor in therapy selection. Here, we analyze main evidence in literature on the predicting value of comorbidity assessment on outcome and management of CLL patients receiving novel agents.

引用

页码：356 / 361

页数：6

共 54 条

[1] Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model [J].

Baumann, Tycho ;

Delgado, Julio ;

Santacruz, Rodrigo ;

Martinez-Trillos, Alejandra ;

Royo, Cristina ;

Navarro, Alba ;

Pinyol, Magda ;

Rozman, Mara ;

Pereira, Arturo ;

Villamor, Neus ;

Aymerich, Marta ;

Lopez, Cristina ;

Carrio, Anna ;

Montserrat, Emili .

HAEMATOLOGICA, 2014, 99 (10) :1599-1604

[2] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[3] Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies [J].

Burger, Jan A. ;

Cramer, Paula ;

Barr, Paul M. ;

Dilhuydy, Marie-Sarah ;

Mato, Anthony ;

Byrd, John C. ;

Chang, Stephen ;

Graef, Thorsten ;

Lin, Tony ;

Tedeschi, Alessandra .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) :175-180

[4] Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab [J].

Byrd, John C. ;

Hillmen, Peter ;

O'Brien, Susan ;

Barrientos, Jacqueline C. ;

Reddy, Nishitha M. ;

Coutre, Steven ;

Tam, Constantine S. ;

Mulligan, Stephen P. ;

Jaeger, Ulrich ;

Barr, Paul M. ;

Furman, Richard R. ;

Kipps, Thomas J. ;

Thornton, Patrick ;

Moreno, Carol ;

Montillo, Marco ;

Pagel, John M. ;

Burger, Jan A. ;

Woyach, Jennifer A. ;

Dai, Sandra ;

Vezan, Remus ;

James, Danelle F. ;

Brown, Jennifer R. .

BLOOD, 2019, 133 (19) :2031-2042

[5] THE USE OF THE KARNOFSKY PERFORMANCE SCALE IN DETERMINING OUTCOMES AND RISK IN GERIATRIC OUTPATIENTS [J].

CROOKS, V ;

WALLER, S ;

SMITH, T ;

HAHN, TJ .

JOURNALS OF GERONTOLOGY, 1991, 46 (04) :M139-M144

[6] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial [J].

Eichhorst, Barbara ;

Fink, Anna-Maria ;

Bahlo, Jasmin ;

Busch, Raymonde ;

Kovacs, Gabor ;

Maurer, Christian ;

Lange, Elisabeth ;

Koeppler, Hubert ;

Kiehl, Michael ;

Soekler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Koechling, Georg ;

Ploeger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Trneny, Marek ;

Fischer, Kirsten ;

Doehner, Harmut ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Boettcher, Sebastian ;

Hallek, Michael .

LANCET ONCOLOGY, 2016, 17 (07) :928-942

[7] Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial [J].

Fischer, Kirsten ;

Bahlo, Jasmin ;

Fink, Anna Maria ;

Goede, Valentin ;

Herling, Carmen Diana ;

Cramer, Paula ;

Langerbeins, Petra ;

von Tresckow, Julia ;

Engelke, Anja ;

Maurer, Christian ;

Kovacs, Gabor ;

Herling, Marco ;

Tausch, Eugen ;

Kreuzer, Karl-Anton ;

Eichhorst, Barbara ;

Boettcher, Sebastian ;

Seymour, John F. ;

Ghia, Paolo ;

Marlton, Paula ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Doehner, Hartmut ;

Stilgenbauer, Stephan ;

Hallek, Michael .

BLOOD, 2016, 127 (02) :208-215

[8] Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax [J].

Frustaci, Anna Maria ;

Biagi, Annalisa ;

Chiarenza, Annalisa ;

Coscia, Marta ;

Ciolli, Stefania ;

Laurenti, Luca ;

Sportoletti, Paolo ;

Reda, Gianluigi ;

Varettoni, Marzia ;

Mauro, Francesca Romana ;

Murru, Roberta ;

Barate, Claudia ;

Greco, Antonino ;

Borella, Chiara ;

Zamprogna, Giulia ;

Martino, Enrica Antonia ;

Vitale, Candida ;

Morelli, Francesca ;

Fresa, Alberto ;

Guarente, Valerio ;

Noto, Alessandro ;

Postorino, Massimiliano ;

Cairoli, Roberto ;

Montillo, Marco ;

Del Poeta, Giovanni ;

Tedeschi, Alessandra .

BLOOD, 2020, 136

[9] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia [J].

Furman, Richard R. ;

Sharman, Jeff P. ;

Coutre, Steven E. ;

Cheson, Bruce D. ;

Pagel, John M. ;

Hillmen, Peter ;

Barrientos, Jacqueline C. ;

Zelenetz, Andrew D. ;

Kipps, Thomas J. ;

Flinn, Ian ;

Ghia, Paolo ;

Eradat, Herbert ;

Ervin, Thomas ;

Lamanna, Nicole ;

Coiffier, Bertrand ;

Pettitt, Andrew R. ;

Ma, Shuo ;

Stilgenbauer, Stephan ;

Cramer, Paula ;

Aiello, Maria ;

Johnson, Dave M. ;

Miller, Langdon L. ;

Li, Daniel ;

Jahn, Thomas M. ;

Dansey, Roger D. ;

Hallek, Michael ;

O'Brien, Susan M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :997-1007

[10]

Gill D, 2014, ASH BLOOD, P124

← 1 2 3 4 5 6 →